KRAS and neoplasm: The effectiveness of KYA1797K on the inhibition of cetuximab-resistant KRAS-mutated CRC cells is shown by both in vitro and in vivo studies using the mouse xenograft tumor model generated from CRC cells harboring KRAS mutations.